Geron Co. (NASDAQ:GERN) Given Average Rating of “Buy” by Brokerages

Shares of Geron Co. (NASDAQ:GERN) have been assigned a consensus rating of “Buy” from the twelve brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation, nine have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $6.91.

A number of research firms have recently commented on GERN. B. Riley lowered their target price on Geron from $5.50 to $3.50 and set a “buy” rating on the stock in a research note on Tuesday. HC Wainwright reiterated a “buy” rating and set a $9.00 target price on shares of Geron in a research note on Tuesday, December 10th. Barclays upgraded Geron to a “strong-buy” rating in a research note on Friday, November 29th. Finally, Needham & Company LLC lifted their target price on Geron from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Monday, January 13th.

Institutional Investors Weigh In On Geron

Hedge funds and other institutional investors have recently modified their holdings of the stock. RTW Investments LP bought a new stake in shares of Geron during the third quarter valued at about $200,268,000. Nvest Financial LLC bought a new stake in shares of Geron during the fourth quarter valued at about $693,000. Janus Henderson Group PLC grew its holdings in shares of Geron by 140.0% during the third quarter. Janus Henderson Group PLC now owns 22,565,846 shares of the biopharmaceutical company’s stock worth $102,193,000 after purchasing an additional 13,163,889 shares in the last quarter. Barclays PLC grew its holdings in shares of Geron by 114.9% during the third quarter. Barclays PLC now owns 1,299,912 shares of the biopharmaceutical company’s stock worth $5,902,000 after purchasing an additional 694,931 shares in the last quarter. Finally, Intech Investment Management LLC purchased a new position in shares of Geron during the third quarter worth about $1,102,000. 73.71% of the stock is currently owned by institutional investors.

Geron Trading Down 3.4 %

NASDAQ GERN opened at $2.54 on Friday. The stock has a market capitalization of $1.54 billion, a price-to-earnings ratio of -7.94 and a beta of 0.53. Geron has a one year low of $1.64 and a one year high of $5.34. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74. The business’s fifty day moving average is $3.16 and its 200-day moving average is $3.89.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.